文献速递乳房整形与再造创面修复

931例经腋窝反向顺序内镜保乳术的手术安全性与风险因素回顾性研究

Surgical Safety and Risk Factors in 931 Consecutive Trans-axillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomies: A Retrospective Study.
PubMed 文献 · Plast Reconstr Surg · 2026-03-13

该回顾性研究分析727例患者共931例经腋窝反向顺序内镜保乳术(R-E-NSM),总体并发症率14.31%,主要并发症率2.20%。D罩杯及以上是主要并发症的独立风险因素,乳房下垂和辅助化疗是任何并发症的独立风险因素,而术前或双平面假体再造及辅助化疗增加手术部位感染风险。

要点

  • R-E-NSM总体并发症率14.31%,主要并发症率2.20%
  • D罩杯及以上是主要并发症独立风险因素(OR 16.00)
  • 乳房下垂和辅助化疗增加任何并发症风险

核心结论

  • R-E-NSM是治疗乳腺良恶性疾病的安全选择,但需特别关注乳房体积较大(罩杯≥D)的患者。

研究设计与样本

  • 回顾性分析2020年5月至2023年9月接受R-E-NSM的患者临床数据,共931例手术、727例患者,采用多因素logistic回归识别并发症独立风险因素。

主要发现

  • 618例(85.00%)行乳房再造,总体并发症率14.31%,主要并发症率2.20%。
  • D罩杯及以上是主要并发症独立风险因素(OR 16.00;95% CI 1.89-135.2;P=0.01)。
  • 乳房下垂I级(OR 1.96;95% CI 1.13-3.43;P=0.02)和II级(OR 1.77;95% CI 1.01-3.90;P=0.046)及辅助化疗(OR 1.76;95% CI 1.05-2.96;P=0.03)是任何并发症独立风险因素。
  • 手术部位感染独立风险因素包括胸肌前假体再造(OR 4.62;95% CI 1.04-20.59;P=0.045)、双平面假体再造(OR 6.87;95% CI 1.55-30.45;P=0.01)和辅助化疗(OR 2.15;95% CI 1.08-4.28;P=0.03)。
  • 晚期美容修整率1.54%,中位随访30.20个月,局部复发和远处转移率均为1.00%。

临床怎么用

  • 对罩杯≥D的患者应特别关注主要并发症风险,加强围手术期管理。
  • 对乳房下垂或拟行辅助化疗的患者,应警惕任何并发症风险。
  • 选择胸肌前或双平面假体再造及辅助化疗患者,需重点预防手术部位感染。

局限性

  • 回顾性研究设计,需长期对比研究进一步验证R-E-NSM的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The trans-axillary reverse-sequence endoscopic nipple-sparing mastectomy (R-E-NSM) technique demonstrates advantages in operative efficiency and cosmetic outcomes. This large-scale study evaluated its surgical safety and identified associated risk factors. METHODS: We retrospectively analyzed clinical data from patients undergoing R-E-NSM between May 2020 and September 2023. Multivariable logistic regression identified independent risk factors for complications. RESULTS: The analysis included 931 R-E-NSM procedures in 727 patients. Breast reconstruction was performed in 618 (85.00%) cases. The overall complication rate was 14.31%, with major complications occurring in 2.20% of cases. A breast cup size of D or larger was an independent risk factor for major complications (OR, 16.00; 95% CI, 1.89-135.2; P = 0.01). Independent risk factors for any complication included breast ptosis (Grade I: OR, 1.96; 95% CI, 1.13-3.43; P = 0.02; Grade II: OR, 1.77; 95% CI, 1.01-3.90; P = 0.046) and adjuvant chemotherapy (ACT) (OR, 1.76; 95% CI: 1.05-2.96; P = 0.03). Independent risk factors for surgical site infection were prepectoral implant-based breast reconstruction (IBBR) (OR, 4.62; 95% CI, 1.04-20.59; P = 0.045), dual-plane IBBR (OR, 6.87; 95% CI, 1.55-30.45; P = 0.01), and ACT (OR, 2.15; 95% CI, 1.08-4.28; P = 0.03). Late cosmetic revisions occurred in 1.54% of patients. At a median follow-up of 30.20 months, locoregional recurrence and distant metastasis rates were both 1.00%. CONCLUSIONS: R-E-NSM is a safe option for treating benign and malignant breast diseases. Special consideration is warranted for patients with larger breast volume (cup size ≥D). Long-term comparative studies are needed to further validate its role.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Yang H, Xie Y, Liang F, et al. Surgical Safety and Risk Factors in 931 Consecutive Trans-axillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomies: A Retrospective Study. Plast Reconstr Surg. 2026. PMID: 41825059. doi:10.1097/PRS.0000000000013027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。